← Back to Search
Use Of All-trans Retinoic Acid In The Treatment Of Acute Promyelocytic Leukemia.
M. Huang, Y. C. Ye, S. Chen, J. Chai, J. Lu, L. Zhao, L. Gu, Z. Wang
Published 1989 · Medicine, Chemistry
Save to my Library
Download PDFAnalyze on Scholarcy
Twenty-four patients with acute promyelocytic leukemia (APL) were treated with all-trans retinoic acid (45 to 100 mg/m2/day). Of these, eight cases had been either nonresponsive or resistant to previous chemotherapy; the other 16 cases were previously untreated. All patients attained complete remission without developing bone marrow hypoplasia. Bone marrow suspension cultures were studied in 15 of the 24 patients. Fourteen of these patients had morphological maturation in response to the retinoic acid (1 mumol/L). Chloroacetate esterase and alpha-naphthyl acetate esterase staining as well as electronmicroscopic examination confirmed that retinoic acid-induced cells differentiated to granulocytes with increased functional maturation (as measured by nitroblue tetrazolium reduction, NBT). The single nonresponder to retinoic acid in vitro was resistant to treatment with retinoic acid but attained complete remission after addition of low-dose cytosine arabinoside (ara-C). During the course of therapy, none of the patients showed any abnormalities in the coagulation parameters we measured, suggesting an absence of any subclinical disseminated intravascular coagulation. The only side effects consisted of mild dryness of the lips and skin, with occasional headaches and digestive symptoms. Eight patients have relapsed after 2 to 5 months of complete remission. The others remain in complete remission at 1+ to 11+ months and are still being followed up. We conclude that all-trans retinoic acid is an effective inducer for attaining complete remission in APL.
This paper references
Human bone marrow culture in agar
BL I 5. Pike (1970)
1 , 25 - Dihydroxyvitamin D 3 : in vitro and in vivo effects on human preleukemic and leukemic cells
HP Koeffler (1985)
Cytochemical identification of monocytes and granulocytes.
L. Yam (1971)
Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia
B. Nilsson (1984)
Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes.
E. J. Gold (1983)
Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations
P. Flynn (1983)
Human bone marrow colony growth in agar‐gel
B. Pike (1970)
Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia.
M. Minden (1979)
Post-Remission Therapy for Acute Myelogenous Leukemia
W. Vogler (1985)
Discrepancy between in-vitro and in-vivo inductions of differentiation by retinoids of human acute promyelocytic leukemia cells in relapse.
K. Sampi (1985)
"Microgranular" acute promyelocytic leukemia: a distinct clinical, ultrastructural, and cytogenetic entity.
H. Golomb (1980)
Kempin 5, Clarkson B: Proplylactic haparin therapy in acute promyelocytic leukemia
RL Drapkin (1978)
Prophylactic heparin therapy in acute promyelocytic leukemia
R. Drapkin (1978)
of patients with acute myeloblastic leukemia
BL Pike (1970)
Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia
Human bone marrow culture in agar gel
BL Pike (1970)
Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications
H. Koeffler (1983)
Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: a new approach to differentiation induction in myelodysplasia and acute myeloid leukaemia.
G. E. Francis (1985)
Treatment of leukemia with low-dose ara-C: a study of 160 cases.
L. Degos (1985)
Acute promyelocytic leukemia: Results of treatment by daunorubicm
J Bernard (1973)
1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells.
H. Koeffler (1985)
Phase I clinical trial of 13 - cis retinoic acid in myelodyplastic syndromes
EJ Gold (1983)
Acute promyelocytic leukemia: results of treatment by daunorubicin.
J. Bernard (1973)
Treatment of leukemia with low dose Ara-C: a study of 159 cases.
S. Castaigne (1985)
Acute promyelocytic leukemia: results of therapy and analysis of 13 cases.
D. Ruggero (1977)
iP: The role of 13-cis retinoic acid in the remission induction of a patient with acute promyelocytic leukemia
Fontana iA (1986)
Proposals for the classification of the acute leukemia
Acute promyelocytic leukemia in 57 previously untreated patients
C. Cordonnier (1985)
Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid.
T. R. Breitman (1980)
1,25-Dihydroxyvitamin D3: in vitro and in vivo effects on human preleukemic and leukemic cells
HP Koeffler (1985)
General clinical toxicology of oral retinoids.
D. Windhorst (1982)
Terminal Differentiation of Human Promyelocytic Leukemic Cells in Primary Culture in Response to Retinoic Acid
T. R. Breitman (1981)
Acute promyelocytic leukemia. A review of literature.
M. Jones (1978)
Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group
J. Bennett (1976)
Cytochemistry of Acute Promyelocytic Leukemia (M3): Leukemic Promyelocytes Exhibit Heterogeneous Patterns in Cellular Differentiation
M. Tomonaga (1985)
Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia.
S. Daenen (1986)
The role of 13 cis‐retinoic acid in the remission induction of a patient with acute promyelocytic leukemia
J. Fontana (1986)
Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations.
P. Flynn (1983)
Acute promyelocytic leukemia: Results of therapy and analysis of I 3 cases
D Ruggero (1977)
Proplylactic haparin therapy in acute promyelocytic leukemia
RL Drapkin (1978)
This paper is referenced by
Arsenic and its origins in traditional Chinese medicine
Thomas R Colledge (2011)
Targeting breast cancer using retinoic acid trifloromethyl chalcone: A promising therapeutic strategy in the treatment of breast cancer
H. Ding (2015)
Molecularly-targeted Strategy and NF-κB in lymphoid malignancies.
R. Horie (2013)
Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.
F. Stevison (2015)
Management of acute promyelocytic leukemia relapse in the ATRA era.
C. Castagnola (1998)
All-trans retinoic acid (ATRA)-induced apoptosis is preceded by G1 arrest in human MCF-7 breast cancer cells.
R. Mangiarotti (1998)
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond
S. Chen (2012)
Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy
M. Luebbert (2008)
Liposomal Drug Delivery of Anticancer Agents: Synthesis, Biophysical Characterization and Biological Studies of Enzyme Sensitive Phospholipid Prodrugs
P. J. Pedersen (2010)
PML nuclear bodies and their spatial relationships in the mammalian cell nucleus.
Elizabeth Batty (2009)
Mechanism-based therapy for leukemia: a lesson from ATRA therapy.
T. Naoe (2001)
RaRF confers RA resistance by sequestering RAR to the nucleolus and regulating MCL1 in leukemia cells
H. Youn (2018)
The role of oncogenes in hematologic malignancies.
L. Boxer (1994)
The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro
P. Baines (2000)
Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells
J. Moreb (2016)
Treatment of hyperproliferative diseases
R. D. Bartlett (1995)
Biphenotypic Acute Leukemia with t(15;17)
M. Scolnik (2005)
Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice.
S. Y. Zhang (1996)
All-trans retinoic acid-incorporated nanoparticles of deoxycholic acid-conjugated dextran for treatment of CT 26 colorectal carcinoma cells
Y. I. Jeong (2013)
Trisenox disrupts MDM2-DAXX-HAUSP complex and activates p53, cell cycle regulation and apoptosis in acute leukemia cells
S. Kumar (2018)
4162 TITLE : Regulation of Epidermal Growth Factor Receptor Expression by PML in Human Breast Cancer
Pharmacogenomics of Primary Blood Cancer Cells
M. Oles (2017)
The acute promyelocytic leukemia-associated protein, promyelocytic leukemia zinc finger, regulates 1,25-dihydroxyvitamin D(3)-induced monocytic differentiation of U937 cells through a physical interaction with vitamin D(3) receptor.
J. O. Ward (2001)
Carnosic acid and promotion of monocytic differentiation of HL60-G cells initiated by other agents.
M. Danilenko (2001)
New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation
K. Kitamura (1997)
Etude de la régulation de l’autophagie au cours de la différenciation des cellules de leucémie aiguë promyélocytaire : rôles dans la survie et la différenciation cellulaire
A. Trocoli (2013)
Genetic and Epigenetic Interactions in in vivo and in vitro Reprogramming
M. Young (2013)
All-trans and 9-cis retinoic acid enhance 1,25-dihydroxyvitamin D3-induced monocytic differentiation of U937 cells.
H. Nakajima (1996)
promyelocytic cell line retinoic acid to induce maturation of a retinoid-resistant myeloid and acute promyelocytic cells and cooperates with all-trans Interferon augments PML and PML / RAR alpha expression in normal
D. Gandini (2002)
Reply to M. Keyhani and N. Mahmoudi
H. Kantarjian (2012)
Intracranial hypertension secondary to all-trans retinoic acid treatment for leukemia: diagnosis and management.
M. Guirgis (2003)
Curative strategies in APL.
H. Iland (2019)See more